CAR T-Cell Therapy Advances in Large B-Cell Lymphoma

Name: CAR T-Cell Therapy Advances in Large B-Cell Lymphoma
Start: 2024-05-22T13:00:00-04:00
End: 2024-05-22T14:00:00-04:00

May 22, 2024

01:00PM - 02:00PM EDT

Online Event

Overview

CAR T-cell therapy is an immunotherapy often used in blood cancers such as leukemia, lymphoma, and multiple myeloma. CAR T-cell therapy represents a paradigm shift in treating patients, especially those with lymphomas not responding (refractory) to traditional chemotherapy. It is still a relatively new treatment, with the first CAR T drug, tisagenlecleucel, approved in 2017.

Advances in this type of treatment are being made every day. There are dozens of clinical trials studying CAR T-cell therapy. Dr. David Miklos joins HealthTree Foundation to discuss these advances and what they mean for DLBCL patients.

Agenda

1:00 PM

Introduction

Kat Richardson

Kat will introduce the event and speaker.

1:05 PM

Presentation

Dr. David Miklos

Dr. Miklos will share his knowledge of advances in CAR T-cell Therapy.

1:35 PM

Questions and Answers

Audience

Type your questions in the chat and Dr. Miklos will answer them!

Speakers & Moderators

Dr. David Miklos

Dr. Miklos is the Chief of Stanford BMT and Cell Therapy Program, which provides 750 cancer cell therapies annually. Their BMT-CT research fosters the development of both laboratory immunologists and clinical translational researchers. Their allogeneic hematopoietic cell transplantation (alloHCT) research is optimizing graft content of HSC, conventional T lymphocyte, and regulatory T cell content in order to cures blood cancers via beneficial graft-v-tumor (GVT) immunity while reducing GVHD risk. Their CAR-T research provides the most direct targeting of cancer and is dramatically improving leukemia and Lymphoma with no GVHD risk. Their goal is to combine graft-engineered allogeneic HCT with CAR-T benefits. The Miklos lab pioneered protein microarray technologies to discover clinically relevant allogeneic antibodies. Their clinical trials established cGVHD therapeutic benefits using anti-B cell drugs rituximab and ibrutinib. More recently, their team developed human correlative assays to optimize CAR-T therapy, including ctDNA MRD, flow cytometry tumor antigen quantification, Immune phenotype CAR-T characterization (CAR-FACS), and single-cell RNA characterization of CAR-T cells. Immunotherapy is revolutionizing cancer treatment, and the Stanford Cancer Cell Therapy Program is developing and evaluating the most promising chimeric antigen T-cell (CAR-T) therapies targeting CD19, CD20, CD22, CD79A, and BCMA.

Kat Richardson

Kat is from Lehi, Utah and is the Health Education Manager for lymphoma. She has worked in healthcare for a decade now, and earned her degree in Community Health Education and Promotion. Kat is passionate about disease prevention as well as improving quality of life and health equity. She enjoys reading, hiking, baking, ice skating, gardening, time with her family and friends, and most of all, spoiling her nieces and nephew.